An Open-Label, Long-Term, Safety and Tolerability Study of VEGF Trap [aflibercept] Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma [non-Hodgkin's lymphoma].
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2016
At a glance
- Drugs Aflibercept (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 16 Apr 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.